Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Molecular targets for treating cognitive dysfunction in schizophrenia Gray JA; Roth BLSchizophr Bull 2007[Sep]; 33 (5): 1100-19Cognitive impairment is a core feature of schizophrenia as deficits are present in the majority of patients, frequently precede the onset of other positive symptoms, persist even with successful treatment of positive symptoms, and account for a significant portion of functional impairment in schizophrenia. While the atypical antipsychotics have produced incremental improvements in the cognitive function of patients with schizophrenia, overall treatment remains inadequate. In recent years, there has been an increased interest in developing novel strategies for treating the cognitive deficits in schizophrenia, focusing on ameliorating impairments in working memory, attention, and social cognition. Here we review various molecular targets that are actively being explored for potential drug discovery efforts in schizophrenia and cognition. These molecular targets include dopamine receptors in the prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, various serotonin receptors, and the gamma-aminobutyric acid (GABA) system.|*Drug Design[MESH]|*Schizophrenic Psychology[MESH]|Antipsychotic Agents/pharmacology/therapeutic use[MESH]|Catechol O-Methyltransferase/drug effects[MESH]|Cognition Disorders/*drug therapy/metabolism/psychology[MESH]|Psychopharmacology[MESH]|Receptors, Dopamine D2/drug effects[MESH]|Receptors, Dopamine/drug effects[MESH]|Receptors, Glutamate/drug effects[MESH]|Receptors, Muscarinic/drug effects[MESH]|Receptors, Neurotransmitter/drug effects[MESH]|Receptors, Nicotinic/drug effects[MESH]|Receptors, Serotonin/drug effects[MESH]|Research[MESH]|Schizophrenia/*drug therapy[MESH] |
